Illumina Says 'Significant Growth' in Sequencing Demand Drove 12-Percent Rise in Q4 Revenue

The company said it is in discussions with several large genome centers about replacing their Genome Analyzers with the newly launched HiSeq 2000, but stressed it is premature to forecast how many customers will opt to trade up.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.